Alemtuzumab

Drugs

Volumn 63, Issue 12, 2003, Pages 1229-1243

  Frampton, James E ^a   Wagstaff, Antona J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALKYLATING AGENT; CD52 ANTIGEN; COTRIMOXAZOLE; CYCLOSPORIN; DIPHENHYDRAMINE; FAMCICLOVIR; FLUDARABINE; GANCICLOVIR; HYDROCORTISONE; MELPHALAN; METHOTREXATE; PARACETAMOL; RITUXIMAB;

ANEMIA; AUTOTRANSPLANTATION; B CELL LEUKEMIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CELL SURFACE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FEVER; DRUG HALF LIFE; DRUG MECHANISM; DYSPNEA; ERYTHROCYTE TRANSFUSION; FATIGUE; FLU LIKE SYNDROME; HEADACHE; HUMAN; HYPOTENSION; LYMPHOCYTE; LYMPHOCYTOPENIA; MONOCYTE; NAUSEA; NEUTROPENIA; OPPORTUNISTIC INFECTION; PANCYTOPENIA; PRURITUS; RASH; REVIEW; RIGOR; SEPTICEMIA; STEM CELL TRANSPLANTATION; T CELL LEUKEMIA; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT OUTCOME; URTICARIA;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; LEUKEMIA, B-CELL; METABOLIC CLEARANCE RATE;

EMESIS;

EID: 0038544611     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200363120-00003     Document Type: Review

References (102)

1. Dumont FJ. CAMPATH (alemtuzumab) for the treatment of chronic lymphocytic leukemia and beyond. Expert Rev Anticancer Ther 2002 Feb; 2 (1): 23-35
2. Andritsos L, Khoury H. Chronic lymphocytic leukemia. Curr Treat Options Oncol 2002 Jun; 3 (3): 225-31
3. Wierda WG, O'Brien S. Immunotherapy of chronic lymphocytic leukemia. Expert Rev Anticancer Ther 2001; 1 (1): 73-83
4. Kalil N, Cheson BD. Management of chronic lymphocytic leukaemia. Drugs Aging 2000 Jan; 16 (1): 9-27
5. Montserrat E. Current and developing chemotherapy for CLL. Med Oncol 2002; 19 Suppl.: S11-9
6. Robak T, Kasznicki M. Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia. Leukemia 2002; 16 (6): 1015-27
7. Keating MJ. Progress in CLL, chemotherapy, antibodies and transplantation. Biomed Pharmacother 2001; 55 (9-10): 524-8
8. Dillman RO. Monoclonal antibodies in the treatment of malignancy: basic concepts and recent developments. Cancer Invest 2001; 19 (8): 833-41
9. Schriever F, Huhn D. New directions in the diagnosis and treatment of chronic lymphocytic leukaemia. Drugs 2003; 63 (10): 953-69
10. Tallman MS. Monoclonal antibody therapies in leukemias. Semin Hematol 2002 Oct; 39 (4 Suppl. 3): 12-9
11. Nemecek ER, Matthews DC. Antibody-based therapy of human leukemia. Curr Opin Hematol 2002 Jul; 9 (4): 316-21
12. Byrd JC, Rai KR. What choices are available for treatment of the patient with chronic lymphocytic leukemia who is fludarabine-refractory? Semin Oncol 2000 Aug; 27 (4): xii-xv; discussion xv-xvi
13. Davis AT. Monoclonal antibody-based therapy of lymphoid neoplasms: what's on the horizon? Semin Hematol 2000 Oct; 37 (4 Suppl. 7): 34-42
14. Waldmann TA, Levy R, Coller BS. Emerging therapies: spectrum of applications of monoclonal antibody therapy. Hematology (Am Soc Hematol Educ Program) 2000; 394-408
15. Rai KR. New biologic therapies. Semin Hematol 1999 Oct; 36 (4 Suppl. 5): 12-7
16. Maloney DG. Advances in immunotherapy of hematologic malignancies. Curr Opin Hematol 1998 Jul; 5 (4): 237-43
17. Dumont FJ. Alemtuzumab (Millennium/ILEX). Curr Opin Investig Drugs 2001 Jan; 2 (1): 139-60
18. Hale G, Xia MQ, Tighe HP, et al. The CAMPATH-1 antigen (CDw52). Tissue Antigens 1990; 35: 118-27
19. Gilleece MH, Dexter TM. Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood 1993 Aug 1; 82 (3): 807-12
20. Ginaldi L, De Martinis M, Matures E, et al. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk Res 1998 Feb; 22 (2): 185-91
21. Xia M-Q, Hale G, Waldmann H. Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen. Mol Immunol 1993; 30: 1089-96
22. Hale G, Bright S, Chumbley G, et al. Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood 1983; 62: 873-82
23. Hale G, Clark M, Waldmann H. Therapeutic potential of rat monoclonal antibodies: isotype specificity of antibody-dependent cell-mediated cytotoxicity with human lymphocytes. J Immunol 1985; 134: 3056-61
24. Dyer MJS, Hale G, Hayhoe FGJ, et al. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood 1989; 73: 1431-9
25. Byrd JC, Shinn CA, Jansure J, et al. CAMPATH-1H induces apoptosis in human chronic lymphocytic leukemia cells (CLL) in vitro independent of complement mediated lysis or Fca receptor ligation [abstract no. 556]. Blood 1999 Nov 15; 94 Suppl. 1, Pt 1: 126a
26. Bannerji R, Kitada S, Flinn IW, et al. Campath-1H antibody induces transmembrane signaling in vitro and in vivo in patients with chronic lymphocytic leukemia (CLL) and promotes tumor clearance in part through caspase mediated apoptosis [abstract no. 3359]. Blood 2001 Nov 16; 98 (Pt 1): 808a
27. Dyer MJ. The role of CAMPATH-1 antibodies in the treatment of lymphoid malignancies. Semin Oncol 1999 Oct; 26 (5 Suppl. 14): 52-7
28. Flynn JM, Byrd JC. Campath-1H monoclonal antibody therapy. Curr Opin Oncol 2000 Nov; 12 (6): 574-81
29. Hale G, Phillips JM. Clinical trials with CAMPATH-1 and other monoclonal antibodies. Biochem Soc Trans 1995 Nov; 23 (4): 1057-63
30. Waldmann H. A personal history of the CAMPATH-1H antibody. Med Oncol 2002; 19 Suppl.: S3-9
31. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002 May 15; 99 (10): 3554-61
32. Osterborg A, Werner A, Halapi E, et al. Clonal CD8pos and CD52neg T cells are induced in responding B cell lymphoma patients treated with Campath-1H (anti-CD52). Eur J Haematol 1997 Jan; 58 (1): 5-13
33. Rawstron AC, Davies FE, Evans PA, et al. CAMPATH1H therapy for patients with refractory chronic lymphocytic leukaemia [abstract no. 97]. Br J Haematol 1998 May; 101 Suppl. 1: 46
34. Hertenstein B, Wagner B, Bunjes D, et al. Emergence of CD52neg, phosphatidylinositolgycan-anchor- deficient T lymphocytes after in vivo application of Campath-1H for refractory B-cell non-Hodgkin lymphoma. Blood 1995 Aug 15; 86: 1487-92
35. Birhiray RE, Shaw G, Guldan S, et al. Phenotypic transformation of CD52pos to CD52neg leukemic T cells as a mechanism for resistance to CAMPATH-1H. Leukemia 2002 May; 16 (5): 861-4
36. Kennedy B, Forsyth PD, Smith GM, et al. CAMPATH-1H therapy does not affect PBSC collection and engraftment in patients with CLL previously treated with fludarabine [abstract no. 786]. Hematol J 2000 Jun; 1 Suppl. 1: 201
37. Ilex Pharmaceuticals. Campath (Alemtuzumab) package insert. San Antonio (TX): Ilex Pharmaceuticals, 2002 Jan
38. Isaacs JD, Manna VK, Rapson N, et al. Campath-1H in rheumatoid arthritis: an intravenous dose-ranging study. Br J Rheumatol 1996; 260: 231-40
39. Rebello P, Hale G. Pharmacokinetics of CAMPATH-1H: assay development and validation. J Immunol Methods 2002 Feb 1; 260 (1-2): 285-302
40. Cwynarsky K, Rebello P, Eades A, et al. Serum levels of Campath-1H in recipients of unrelated BMT [abstract no. 828]. Hematol J 2000 Jun; 1 Suppl. 1: 212
41. Rebello P, Cwynarski K, Varughese M, et al. Pharmacokinetics of CAMPATH-1H in BMT patients. Cytotherapy 2001; 3 (4): 261-7
42. Morris E, Rebello P, Thomson K, et al. Pharmacokinetics of Campath-1H in vivo T cell depletion in non-myeloablative allogeneic transplants: relevance for early adoptive immunotherapy [abstract no. 1998]. Blood 2001 Nov 16; 98 (Pt 1): 478a
43. Keating MJ, O'Brien S, Kontoyiannis D, et al. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma 2002 Sep; 43 (9): 1755-62
44. Giles FJ, O' Brien SM, Santini V, et al. Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukaemia: a phase II study. Leuk Lymphoma 1999 Dec; 36 (1-2): 57-65
45. Lundin J, Kimby E, Bjorkholm M, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002 Aug 1; 100 (3): 768-73
46. Cheson BD, Bennet JM, Rai KR, et al. Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored Working Group. Am J Haematol 1988; 29: 152-63
47. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996 Jun 15; 87 (12): 4990-7
48. Osterborg A, Dyer MJ, Bunjes D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. J Clin Oncol 1997 Apr; 15 (4): 1567-74
49. Ferrajoli A, O'Brien SM, Williams ML, et al. Campath-1H in refractory hematological malignancies expressing CD-52. A phase II clinical trial of 68 patients [abstract no. 1541]. Blood 2001 Nov 16; 98 (Pt 1): 366a
50. Rai KR, Freter CE, Mercier RJ, et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002 Sep 15; 20 (18): 3891-7
51. McCune SL, Gockerman JP, Moore JO, et al. Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Leuk Lymphoma 2002 May; 43 (5): 1007-11
52. Stilgenbauer S, Scherer K, Krober A, et al. Campath-1H in refractory B-CLL - complete remission despite p53 gene mutation [abstract no. 3211]. Blood 2001 Nov 16; 98 (Pt 1): 771a
53. Jensen M, Schulz H, Winkler U, et al. Treatment of relapsed fludarabine resistant B-cell chronic lymphocytic leukemia with Campath-1H (anti-CD52 antibody) [abstract no. 0179]. Onkologie 1999 Aug; 22 Suppl. 1: 53
54. Rawstron AC, Davies FE, Morgan GJ, et al. Monitoring of residual disease after CAMPATH-1H therapy of refractory chronic lymphocytic leukaemia [abstract no. 429]. Blood 1998 Nov 15; 92 Suppl. 1, Pt 1: 105a
55. Bowen AL, Zomas A, Emmett E, et al. Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia. Br J Haematol 1997 Mar; 96 (3): 617-9
56. Lundin J, Kimhy E, Mellstedt H, et al. Hematological recovery after administration of subcutaneous alemtuzumab (MabCampath) in previously untreated versus refractory B-CLL [abstract no. 3177]. Blood 2002 Nov 16; 100 (Pt 1): 805a
57. Rai KR, Coutre S, Rizzieri D, et al. Efficacy and safety of alemtuzumab (Campath-1H) in refractory B-CLL patients treated on a compassionate basis [abstract no. 1538]. Blood 2001 Nov 16; 98 (Pt 1): 365a
58. Rai KR, Keating MJ, Coutre S, et al. Patients with refractory B-CLL and T-PLL treated with alemtuzumab (Campath) on a compassionate basis. A report on efficacy and safety of CAM 511 trial [abstract no. 3165]. Blood 2002 Nov 16; 100 (Pt 1): 802a
59. Rai K, Hallek M. Future prospects for alemtuzumab (MabCampath). Med Oncol 2002; 19 Suppl.: S57-63
60. Rai KR, Janson D, Driscoll N, et al. Varying modes of maintenance therapy with Campath-1H in chronic lymphocytic leukemia (CLL) [abstract no. 1099]. 38th Annual Meeting of the American Society of Clinical Oncology; 2002 May 18-21; Orlando (FL), Pt 1: 275a
61. Pangalis GA, Dimopoulou MN, Angelopoulou MK, et al. Campath-1H in B-chronic lymphocytic leukemia: report on a patient treated thrice in a 3 year period. Med Oncol 2000; 17: 70-3
62. Tison B, Bolin R, Lill J, et al. Benefits of repeated courses of alemtuzumab (Campath) in patients with relapsed/refractory B-CLL [abstract no. 4920]. Blood 2001; 98: 293b-4b
63. Thieblemont C, Bouafia F, Hornez E, et al. Maintenance therapy with a monthly injection of Campath-1H in refractory chronic leukemia and NHL patients [abstract no. 3178]. Blood 2002 Nov 16; 100 (Pt 1): 805a
64. Nabhan C, Dyer MJ, Rosen ST. Current status of monoclonal antibody therapy for chronic lymphocytic leukemia. Oncology 2003; 17 (2): 253-62
65. Faderl S, Thomas DA, O'Brien S, et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 2003; 101 (9): 3413-5
66. Nabhan C, Tallman MS, Riley MB, et al. Phase 1 study of rituximab and CAMPATH-1H in patients with relapsed or refractory chronic lymphocytic leukemia [abstract no. 1536]. Blood 2001 Nov 16; 98 (Pt 1): 365a
67. Nathan C, Rosen ST. Conceptual aspects of combining rituximab and Campath-1H in the treatment of chronic lymphocytic leukemia. Semin Oncol 2002 Feb; 29 (1 Suppl. 2): 75-80
68. Elter T, Borchmann P, Schulz H, et al. Development of a new, four-weekly schedule (FluCam) with concomitant application of Campath-1H and fludarabine in patients with relapsed/refractory CLL [abstract no. 3169]. Blood 2002 Nov 16; 100 (Pt 1): 803a
69. Kennedy B, Rawstron A, Carter C, et al. Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood 2002 Mar 15; 99 (6): 2245-7
70. Rai KR, Byrd JC, Peterson BL, et al. A phase II trial of fludarabine followed by alemtuzumab (Campath-1H) in previously untreated chronic lymphocytic leukemia (CLL) patients with active disease: Cancer and Leukaemia Group B (CALGB) Study 19901 [abstract no. 772]. Blood 2002 Nov 16; 100 (Pt 1): 205a
71. Montillo M, Tedeschi A, Cafro AM, et al. Sequential subcutaneous administration of CAMPATH-1H as treatment of minimal residual disease in CLL patients responding to fludarabine (FAMP) [abstract no. 3175]. Blood 2002 Nov 16; 100 (Pt 1): 804a
72. Montillo M, Cafro AM, Tedeschi A, et al. Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine. Haematologica 2002 Jul; 87 (7): 695-700
73. Osterborg A, Fassas AS, Anagnostopoulos A, et al. Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. Br J Haematol 1996 Apr; 93 (1): 151-3
74. Cao TM, Coutre SE. T-cell prolymphocytic leukaemia: update and focus on alemtuzumab (Campath-1H). Hematology 2003; 8 (1): 1-6
75. Matutes E. T-cell prolymphocytic leukemia. Cancer Control 1998 Jan; 5 (1): 19-24
76. Dearden CE, Matutes E, Catovsky D. Alemtuzumab in T-cell malignancies. Med Oncol 2002; 19 Suppl.: S27-32
77. Dearden CE, Matutes E, Cazin B, et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood 2001 Sep 15; 98 (6): 1721-6
78. Keating MJ, Cazin B, Coutre S, et al. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol 2002 Jan 1; 20 (1): 205-13
79. Lundin J, Hagberg H, Repp R, et al. Phase II study of alemtuzumab (anti-CD52 monoclonal antibody, Campath-1H) in patients with advanced mycosis fungoides/Sezary syndrome. Blood 2003 Jan 23
80. Lundin J, Osterborg A, Brittinger G, et al. CAMPATH-1H monoclonal antibody in therapy for previously treated lowgrade non-Hodgkin's lymphomas: a phase II multicenter study. J Clin Oncol 1998; 16 (10): 3257-63
81. Hale G, Jacobs P, Wood L, et al. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells. Bone Marrow Transplant 2000; 26: 69-76
82. Hale G. Alemtuzumab in stem cell transplantation. Med Oncol 2002; 19 Suppl.: S33-47
83. Hale G, Slavin S, Goldman JM, et al. Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning? Bone Marrow Transplant 2002 Dec; 30 (12): 797-804
84. Hale G, Cobbold S, Novitzky N, et al. CAMPATH-1 antibodies in stem-cell transplantation. Cytotherapy 2001; 3 (3): 145-64
85. Chakrabarti S, Fegan C, Milligan D. Campath 1-H in the bag for T cell depletion in allogeneic peripheral blood progenitor cell transplantation from matched family and unrelated donors reduces both acute and chronic GvHD and limits transplant-related mortality [abstract no. 0277]. Bone Marrow Transplant 2002 Mar; 29 Suppl. 2: S46
86. Rizzieri DA, Long GD, Vredenburgh JJ, et al. Chimerism mediated immunotherapy using Campath T cell depleted peripheral blood progenitor cells with nonablative therapy provides reliable, durable allogeneic engraftment [abstract no. 2241]. Blood 2000 Nov 16; 96 (Pt 1): 521a
87. Jacobs P, Wood L, Hale G, et al. Further experience with campath 1H in monoclonal antibody for T-cell depletion of peripheral mononuclear cells in-the-bag [abstract no. 751]. Hematol J 2000 Jun; 1 Suppl. 1: 192
88. Bunjes D. T cell depletion of allogeneic stem cell grafts with anti-CD 52 monoclonal antibodies: the Ulm experience from 1983-1999. Transfus Sci 2000 Oct; 23 (2): 151-62
89. Kottaridis PD, Milligan DW, Chopra R, et al. In vivo CAMPATH-1H prevents graft-versus host disease following nonmyeloablative stem cell transplantation. Blood 2000; 96 (7): 2419-25
90. Byrne J, Donovan L, Davy B, et al. Pre-transplant serotherapy with Campath 1H or ATG is effective in preventing GvHD in patients undergoing allogeneic PBSC transplantation from matched unrelated donors [abstract no. P657]. Bone Marrow Transplant 2002 Mar; 29 Suppl. 2: S173-4
91. Buggins AG, Mufti GJ, Salisbury J, et al. Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab. Blood 2002 Sep 1; 100 (5): 1715-20
92. Klangsinsirikul P, Carter GI, Byrne JL, et al. Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution. Blood 2002 Apr 1; 99 (7): 2586-91
93. Ho AYL, Kenyon M, El-Hemaldi I, et al. Reduced-intensity allogeneic hematopoietic stem cell transplantion with alemtuzumab conditioning regimens: survival does not plateau until after day 200. Blood 2003; 101 (2): 779-80
94. O'Brien SM, Thomas DA, Cortes J, et al. Campath-1H for minimal residual disease in CLL [abstract no. 1132]. 37th Annual Meeting of the American Society of Clinical Oncology 2001; 20: 284a
95. Dyer MJS, Kelsey SM, Mackay HJ, et al. In vivo 'purging' of residual disease in CLL with Campath-1H. Br J Haematol 1997 Jun; 97 (3): 669-72
96. Kennedy B, Rawstron AC, Evans P, et al. CAMPATH-1H therapy in 29 patients with refractory CLL: 'true' complete remission is an attainable goal [abstract no. 2683]. Blood 1999 Nov 15; 94 Suppl. 1, Pt 1: 603
97. Smith JA. Alemtuzumab: a new option for refractory chronic lymphocytic leukemia? Cancer Pract 2001 Jul-2001 31; 9 (4): 211-3
98. Kennedy B, Hillmen P. Immunological effects and safe administration of alemtuzumab (MabCampath) in advanced B-CLL. Med Oncol 2002; 19 Suppl.: S49-55
99. Pangalis GA, Dimopoulou MN, Angelopoulou MK, et al. Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders. Med Oncol 2001; 18 (2): 99-107
100. Perkins JG, Flynn JM, Howard RS, et al. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphoma: implications for clinical trials in these patient populations. Cancer 2002; 94 (7): 2033-9
101. Nguyen DD, Cao TM, Dugan K, et al. Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Clin Lymphoma 2002 Sep; 3 (2): 105-10
102. Williams TE, Roach J, Rugg T, et al. Frequency of cytomegalovirus pneumonia following alemtuzumab (Campath) treatment in lymphoid malignancies: review of 1538 patients [abstract no. 4923]. Blood 2001 Nov 16; 98 (Pt 2): 294b